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A B S T R A C T
The purpose of this study was to investigate the neuroprotective effect of a water-soluble formulation of
coenzyme Q10 (WS-CoQ10) in PC12 cells exposed to cisplatin, a chemotherapeutic agent with a dose-
limiting factor due to neurotoxicity. In the cytokinesis-block micronucleus cytome assay (CBMN Cyt),
WS-CoQ10 (at concentrations of 0.1, 0.5 and 1.0 mg mL1) protected PC12 cells from cisplatin-induced
DNA damage (0.1 mg mL1), reducing the frequency of micronuclei (MNi) and nuclear buds (NBUDs).
WS-CoQ10 did not alter the mRNA expression levels of Tp53 (at a concentration of 1.0 mg mL1) and
exhibited neuroprotective activity by stimulating cisplatin-inhibited neurite outgrowth in nerve growth
factor (NGF)-differentiated PC12 cells (at a concentration of 0.1 mg mL1). In conclusion, WS-CoQ10
protected the PC12 cells from cisplatin-induced DNA damage and neurotoxicity. Moreover, the
neuroprotective effects of WS-CoQ10 suggest a possible application in chemotherapeutic protocols.
 2013 Elsevier Inc. 
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In recent years, several natural antioxidants have been studied
as potential neuroprotective agents and have produced promising
results in both in vivo and in vitro models of neurodegenerative
diseases and neuronal toxicity (Argyriou et al., 2006; Kelsey et al.,
2010; Shabani et al., 2012). One of these natural antioxidants,
coenzyme Q10 (CoQ10) or ubiquinone, is a liposoluble provitamin
that is endogenously synthesised and naturally found in various
food items, such as beef, chicken, ﬁsh, eggs, nuts, vegetables and
cereals (Pravst et al., 2010).
CoQ10 is located in the membranes of cellular organelles
such as peroxisomes, lysosomes and, predominantly, the inner
mitochondrial membrane, where it is involved in reactions that
are necessary to carry out oxidative phosphorylation via the
electron transport chain (Crane, 2001). CoQ10 has attracted
attention because it functions as a mitochondrial antioxidantAbbreviations: CoQ10, coenzyme Q10; NGF, nerve growth factor; MNi, micronuclei;
NBUDs, nuclear buds; NPBs, nucleoplasmatic bridges; OD, optical density; ROS,
reactive oxygen species; WS-CoQ10, water-soluble formulation of coenzyme Q10.
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Open access under the Elsevier OA license.(Kelso et al., 2001), decreasing DNA damage and maintaining
genome stability (McCarthy et al., 2004).
CoQ10 has been safely administered in animal studies (Ferrante
et al., 2002; Matthews et al., 1998) and human trials of
mitochondrial disorders and Parkinson’s and Huntington’s disease
(Mancuso et al., 2010). Due to the low water solubility of CoQ10
(Balakrishnan et al., 2009), few in vitro studies using culture
medium have been conducted. Thus, a water-soluble formulation
of CoQ10 (WS-CoQ10) was developed (Sikorska et al., 2003); WS-
CoQ10 is readily taken up by cells when added to culture medium
and has shown protective activity against neurotoxic agents in
neuronal cell systems (McCarthy et al., 2004; Somayajulu et al.,
2005).
Some chemotherapeutic agents, such as cisplatin, have adverse
neurotoxic effects that manifest as peripheral neuropathies
(Cavaletti et al., 2002). Cisplatin, a chemotherapeutic agent used
in the treatment of several cancers (Tomaszewski and Busselberg,
2007; Wang and Lippard, 2005), is directly absorbed by the sensory
nerves and predominantly causes sensory neuropathy (Roelofs
et al., 1984). Cisplatin-induced peripheral neuropathy is dose-
dependent and occurs in approximately 30% of patients, with 20%
of patients forced to discontinue chemotherapy treatment due to
the adverse effects (Podratz et al., 2011).
The mechanisms by which cisplatin induces neuronal cell death
are unclear; however, evidence suggests that the cells may
undergo changes in p53 protein expression (Park et al., 2000)
C. da Silva Machado et al. / NeuroToxicology 36 (2013) 10–16 11and DNA damage (Hetman et al., 2010). Cisplatin interacts with
both nuclear and mitochondrial DNA, forming adducts that
interfere with gene transcription and the synthesis of proteins
involved in the maintenance of neurons, thus contributing to its
cytotoxicity and neurotoxicity (Podratz et al., 2011). Moreover, the
p53 protein is important in the cell death pathway in sensory
neurons undergoing cisplatin treatment (Park et al., 2000, 2008).
PC12 cells, derived from an adrenal tumour, possess neuronal
cell features and respond positively to nerve growth factor (NGF),
differentiating into neuron-like cells (Yoo et al., 2004). PC12 cells
are used as a model to investigate the neurotoxic effects of
chemotherapeutic agents and may become an important tool for
studies of CoQ10, as the cellular distribution of CoQ10 in PC12 cells
is similar to that observed in the rat brain (Saito et al., 2009).
Furthermore, PC12 cells are Tp53 proﬁcient, which is a recom-
mended feature for cells used in genotoxicity studies (Kirkland
et al., 2007).
As previously demonstrated, antioxidant agents can reduce or
inhibit cisplatin-induced toxicity (Dos Santos et al., 2012;
Mendonca et al., 2009; Serpeloni et al., 2011); however, it is not
known whether the neuroprotective effect of WS-CoQ10 can be
extended to cisplatin-induced neurotoxicity. To investigate this
possibility, the protective effect of WS-CoQ10 after cisplatin
treatment was evaluated in PC12 cells. A cytokinesis-block
micronucleus cytome assay (CBMN Cyt) (Fenech, 2007) and an
alkaline single cell gel electrophoresis (comet) assay (Tice et al.,
2000) were used to evaluate DNA damage. Quantitative real time
PCR (RT-qPCR) was used to determine the mRNA expression levels
of Tp53, and neurotoxicity was evaluated in the NGF-differentiated
PC12 cells using a neurite outgrowth assay. Glutathione (GSH)
and glutathione disulphide (GSSG) were determined using an
enzymatic recycling method.
2. Materials and methods
2.1. Chemicals
WS-CoQ10 (US patent # 6,045,826), which uses polyoxyethanyl
a-tocopheryl sebacate (PTS) as a carrier, was kindly provided by
Dr. Marianna Sikorska of the National Research Council (NRC),
Ottawa, Canada. Cisplatin (cis-diamminedichloroplatinum II; CAS
15663-27-1) was obtained from Quiral Quı´mica do Brasil
(Platinil1, Juiz de Fora, Brazil). Cytochalasin B (CAS 14930-96-2),
ethidium bromide (CAS 1239-45-8), trypan blue (CAS 72-57-1),
Giemsa (CAS 51811-82-6), penicillin (CAS 61-33-6), streptomycin
(CAS 57-92-1), glutathione reductase (GR, No. G-4251), b-NADPH
(No. N-7505), GSH (No. G-4251) and GSSG (No. G-6654) were
purchased from Sigma–Aldrich (St. Louis, MO, USA). RPMI medium
1640, heat-inactivated foetal bovine serum and heat-inactivated
horse serum were purchased from Gibco (Carlsbad, CA, USA).
TRIzol1 reagent (No. 15596-026), low melting point agarose (CAS
9012-36-6) and normal melting point agarose (CAS 9012-36-6)
were purchased from Invitrogen (Carlsbad, CA, USA). Mouse
laminin puriﬁed protein (No. CC095) and nerve growth factor
(NGF; No. NC011) were obtained from Millipore (Billerica, MA,
USA). Dimethylsulphoxide (DMSO, CAS 67-68-5) was purchased
from Merck Chemicals (Rio de Janeiro, RJ, Brazil). The other
chemicals used were of analytical grade and the purest quality
available.
2.2. Cell culture conditions and treatments
Rat pheochromocytoma PC12 cells were derived from the
American Type Culture Collection (No. CRL-1721TM, Rockville, MD,
USA), kindly donated by Dr. Antoˆnio Cardozo dos Santos (FCFRP-
USP). PC12 cells were subcultured two or three times a week, usedbetween the 3rd and 10th passages from the initial passage and
grown in RPMI medium 1640 containing 5% heat-inactivated foetal
bovine serum, 10% heat-inactivated horse serum and a 1%
penicillin/streptomycin mix. The cells were cultured in a humid
atmosphere with 5% CO2, 95% air at 37 8C. The NGF-differentiated
PC12 cells were grown in differentiation medium containing RPMI
medium 1640, 1% heat-inactivated horse serum, 1% penicillin/
streptomycin antibiotic mixture and 50 ng mL1 NGF and were
maintained under the same conditions as those described for PC12
cells.
Non-cytotoxic concentrations of WS-CoQ10 (0.1, 0.5 and
1.0 mg mL1) and cisplatin (0.1 mg mL1) for the CBMN Cyt and
comet assay were established based on preliminary tests for cell
viability and cytostasis (cell viability above 90% in the MTT assay;
percentage of binucleated cells greater than 35%, data not shown)
and conﬁrmed by the trypan blue dye exclusion method (number
of trypan blue dye-excluded cells was >95%). The PC12 cells were
exposed to WS-CoQ10, cisplatin and a combination for 48 h in the
CBMN Cyt assay and for 3 h in the comet assay.
For analysis of the Tp53 mRNA expression levels by RT-qPCR,
the PC12 cells were treated with WS-CoQ10 (1.0 mg mL1),
cisplatin (0.1 mg mL1) or a combination for a period of 48 h. In
the neurite outgrowth assay, non-cytotoxic concentrations of WS-
CoQ10 (0.1 and 1.0 mg mL
1) and cisplatin (10.0 mg mL1) were
predetermined by the MTT assay using NGF-differentiated PC12
cells (data not shown). Cisplatin at a concentration of 10.0 mg mL1
is not cytotoxic and induces high neuritic toxicity in NGF-
differentiated PC12 cells (Klein et al., 2007; Verstappen et al.,
2004). The NGF-differentiated PC12 cells were exposed to test
substances (WS-CoQ10; cisplatin; and WS-CoQ10 + cisplatin) for
24 h; after 24 h, the cisplatin was removed, and the cultures were
re-treated with WS-CoQ10 for an additional 48 h.
In the assay to determine the total GSH, PC12 cells were treated
with WS-CoQ10 (0.1, 0.5 and 1.0 mg mL1), cisplatin (0.1 mg mL1)
or the combination WS-CoQ10 and cisplatin for 24 h. In all
experiments, both the negative and solvent controls were
included. As the solvent control did not differ from the negative
control (p > 0.05) for all parameters evaluated, the results of the
treated groups were compared to the negative control.
2.3. CBMN Cyt assay
The CBMN Cyt assay was carried out according to the protocol of
Fenech (2007) with slight modiﬁcations. Brieﬂy, 1.0  106 PC12
cells were grown for 24 h at 37 8C in 25 cm2 culture ﬂasks (Corning,
Lowell, MA, USA). After 24 h, the medium was replaced, and the
cells were exposed to different concentrations of the test
substances (0.1, 0.5 and 1.0 mg mL1 WS-CoQ10; 0.1 mg mL1
cisplatin; and WS-CoQ10 + cisplatin). Cytochalasin B (ﬁnal con-
centration of 6.0 mg mL1) was added immediately after treatment
of cultures. After 48 h of treatment and cytokinesis blocking, the
cells were collected and centrifuged (1000 rpm for 9 min). PC12
cells were harvested and placed in a hypotonic solution (1% sodium
citrate), ﬁxed using methanol/acetic acid (3/1) and 25 mL
formaldehyde, and the slides were then stained with Giemsa
(5%). For each independent experiment (n = 3), 2000 binucleated
cells with a well-preserved cytoplasm were scored under light
microscopy at 1000 magniﬁcation.
Micronuclei (MNi), nuclear buds (NBUDs) and nucleoplasmic
bridges (NPBs) were identiﬁed according to the recognition criteria
previously described by Fenech (2007). As a measure of cytostasis,
the nuclear division index (NDI) was calculated according to the
following formula: NDI = (M1 + 2M2 + 3M3 + 4M4)/N (Eastmond
and Tucker, 1989), where M1–M4 represent the number of cells
with 1–4 nuclei determined in 500 cells, and N represents the total
number of viable cells scored.
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The comet assay was performed under alkaline conditions in
agreement with the guidelines published by Singh et al. (1988) and
Tice et al. (2000). PC12 cells were seeded at a density of 1  106 in
25 cm2 culture ﬂasks for 24 h and treated with substances of
interest (0.1, 0.5 and 1.0 mg mL1 WS-CoQ10; 0.1 mg mL1
cisplatin; and WS-CoQ10 + cisplatin) for 3 h. Doxorubicin was
used as a positive control (10.0 mg mL1). PC12 cells were
homogenised with low melting point agarose dissolved in Ca2+-
and Mg2+-free phosphate buffer saline (PBS; pH 7.4), transferred to
normal melting point agarose-coated slides and immersed in
freshly prepared lysis solution (2.5 M NaCl, 100 mM EDTA, 10%
DMSO, 1% Triton X-100, 10 mM Tris, pH 10) at 4 8C for 24 h.
Electrophoresis was conducted under standard conditions (25 V,
300 mA, 0.78 V/cm) for 20 min at 4 8C; subsequently, the slides
were washed in a neutralisation buffer (0.4 M Tris–HCl, pH 7.5) for
15 min, dried at room temperature and ﬁxed in absolute ethanol.
The slides were stained with ethidium bromide (2.0 mg mL1) and
immediately analysed under a ﬂuorescence microscope (Axiostar,
Zeiss, Germany) at a 400 magniﬁcation with an excitation ﬁlter of
515–560 nm and a barrier ﬁlter of 590 nm. In all experiments, the
data are based on 100 randomly selected nucleoids (50 nucleoids
from each replicate slide). Nucleoids were analysed using the
software Comet Score (TriTech Corporation, Sumerduck, VA, USA),
and the percentage of DNA (% DNA) in the tail was used as the
parameter for DNA damage.
2.5. RT-qPCR
PC12 cells were collected in TRIzol1 reagent, and total RNA was
extracted using the SV Total Isolation System kit (Promega,
Madison, WI, USA) according the manufacturer’s instructions. The
quality and the integrity of the RNA were assessed by gel
electrophoresis in 1.0% agarose, and the purity was measured
based on the 260/280 and 260/230 ratios. Reverse transcription
reactions were performed using the SuperScriptTM III kit (Invitro-
gen, Carlsbad, CA, USA). For the RT-qPCR reaction, the initial
incubation was 10 min at 95 8C, followed by 34 cycles of
denaturation (95 8C for 15 s) and annealing/extension (60 8C for
60 s). Fluorescent detection with the ABsoluteTM QPCR SYBR1
Green Mix (Invitrogen, Carlsbad, CA, USA) was performed after
each annealing/extension cycle on a CFX96 Real-Time PCR
Detection System (BioRad, CA, USA). Gene speciﬁc primers to
amplify Tp53 and b-actin (housekeeping) were synthesised by
Sigma–Aldrich (St. Louis, MO, USA), and the sequences were as
follows: Tp53-forward: CATCATCACGCTGGAAGACTC; Tp53-re-
verse: TTCAGCTCTCGGAACATCTC; b-actin-forward: TCCTGTGG-
CATCCATGAACT and b-actin-reverse: CCAGGGCAGTAATCTCT-
TTCTTCTG. The relative mRNA expression of Tp53 was normalised
to b-actin using the relative quantiﬁcation method 2DDCt (Livak
and Schmittgen, 2001).
2.6. Neurite outgrowth assay
The Neurite Outgrowth Assay kit (No. NS225, Millipore,
Billerica, MA, USA), which has been validated for PC12 cells, was
used to evaluate neurotoxicity in the NGF-dPC12 cells. The PC12
cells were incubated with differentiation medium for 72 h,
transferred to cell culture inserts previously prepared with a
solution of mouse laminin puriﬁed protein at a concentration of
1.0  106 cells mL1 and treated with different concentrations of
the test substances (0.1 and 1.0 mg mL1WS-CoQ10; 10.0 mg mL1
cisplatin; and WS-CoQ10 + cisplatin). The NGF-dPC12 cells were
washed, ﬁxed, and stained, and the neurites were extracted
according to the protocol described in the Neurite OutgrowthAssay kit. The optical density (OD) was measured using a
spectrophotometer (Shimadzu, Chelmsford, MA, USA) at a
wavelength of 562 nm. The OD values were converted to percent
(%) neurites, and the negative control (NGF-treated cells) was
considered to be 100% of the neurites.
2.7. Total GSH
PC12 cells were seeded at a density of 1  106 in 25 cm2 culture
ﬂasks and treated with test substances (0.1, 0.5 and 1.0 mg mL1
WS-CoQ10; 0.1 mg mL1 cisplatin; and WS-CoQ10 + cisplatin) for
24 h. After the treatments, the total GSH was measured by the
method described by Rahman et al. (2006). PC12 cells were washed
with Ca2+/Mg2+-free PBS, scraped, lysed with ice-cold extraction
buffer (0.1% Triton-X and 0.6% sulphosalicylic acid in 0.1 M
potassium phosphate buffer with 5 mM EDTA, pH 7.5) and
submitted to a process of freezing/defrosting. GSH was measured
by reducing GSSG using GR and NADPH. This assay is based on the
biochemical reaction between GSH and DTNB [5,50-dithio-bis(2-
nitrobenzoic acid)] to form TNB (5-thio-2-nitrobenzoic acid). To
measure the GSSG levels, 100 mL of cells lysed with ice-cold
extraction buffer was mixed with 2-vinyl pyridine (which reacts
only with GSH), and the lysed cells were treated with GR, NADPH
and DTNB. The absorbance was measured at 412 nm using a
microplate reader, taking measurements every minute for
2 minutes (Biotek1, Seattle, WA, USA). Data were compared to
GSH and GSSG standard curves and normalised to 106 cells. The
total GSH represents the sum of the reduced and oxidised GSH in
the sample (GSH + 2GSSG).
2.8. Statistical analysis
All of the results are expressed as the mean  standard deviation
(SD) of three independent experiments (n = 3). Using the GraphPad
Prism 5 program (GraphPad Software, USA), the data were submitted
to a one-way analysis of variance (ANOVA) and Tukey’s post hoc test to
determine statistically signiﬁcant differences (p < 0.05).
3. Results
3.1. WS-CoQ10 reduces DNA damage induced by cisplatin
DNA damage in PC12 cells was evaluated using the CBMN Cyt
and comet assays. All treatments met the criteria established by of
Fenech (2000), with at least 35% of cells appearing binucleated
(data not shown). The parameters evaluated for CBMN Cyt were
the frequency of the micronuclei, nuclear buds and nucleoplasmic
bridges in 1000 binucleated cells and the NDI. In the comet assay,
the % DNA in the tail was evaluated.
The results of the NDI are in Table 1 and show that all of the
treatments (WS-CoQ10, cisplatin and the combination) did not
exhibit cytostatic effects on PC12 cells. The frequency of the MNi,
NBUDs and NPBs found in treatments with WS-CoQ10 (0.1, 0.5 and
1.0 mg mL1) were similar to those observed in the negative
control (Table 1). Among the treatments, there was no statistically
signiﬁcant difference in the frequency of MNi, NBUDs or NPBs in
cells treated with WS-CoQ10. These results indicate that WS-
CoQ10 did not cause DNA damage in PC12 cells at the
concentrations evaluated. Based on the negative results for DNA
damage due to WS-CoQ10, the anti-genotoxic effect of WS-CoQ10
in combination with cisplatin was evaluated.
Cisplatin treatment resulted in a 3.38-fold increase in the
frequency of MNi compared to the negative control (p < 0.05). WS-
CoQ10 signiﬁcantly inhibited the cisplatin-induced MNi, with a
protective effect of approximately 50% when compared to cisplatin
alone (Table 1). The frequency of NBUDs in cisplatin-treated cells
Table 1
The frequency of micronuclei, nuclear buds and nucleoplasmic bridges in 1000 binucleated cells and the nuclear division index of PC12 cells treated with various
concentrations of WS-CoQ10 and cisplatin alone or in combination.
Treatment (mg mL1) BN cells with MNi BN cells with NBUDs BN cells with NPBs NDI mean  SD
Negative control 7.0  1.7 2.5  1.4 0.0  0.0 1.7  0.1
WS-CoQ10 0.1 6.8  1.6 3.2  1.7 0.3  0.8 1.7  0.1
WS-CoQ10 0.5 8.5  2.2 3.2  0.7 0.2  0.5 1.7  0.1
WS-CoQ10 1.0 9.2  1.7 3.7  1.5 0.2  0.5 1.7  0.2
Cisplatin 0.1 23.7  3.9* 9.2  0.9* 1.2  1.3 1.6  0.2
WS-CoQ10 0.1 + cisplatin 0.1 12.3  3.3# 6.5  2.1 0.7  1.5 1.6  0.1
WS-CoQ10 0.5 + cisplatin 0.1 12.0  1.8# 5.6  2.1# 0.8  1.9 1.6  0.2
WS-CoQ10 1.0 + cisplatin 0.1 12.5  1.4# 5.8  2.7# 0.5  1.1 1.6  0.1
BN: binucleated cells; MNi: micronuclei; NBUDs: nuclear buds; NPBs: nucleoplasmic bridges; NDI: nuclear division index. The data represent the mean  SD (standard
deviation) of three independent experiments (n = 3).
* Signiﬁcantly different from negative control (p < 0.05).
# Signiﬁcantly different from cisplatin treatment (p < 0.05).
C. da Silva Machado et al. / NeuroToxicology 36 (2013) 10–16 13increased 3.67-fold when compared with the negative control.
WS-CoQ10 at concentrations 0.5 and 1.0 mg mL1 resulted in a
1.65-fold and 1.57-fold decrease, respectively, in the frequency of
NBUDs induced by cisplatin when compared to cisplatin alone
(p < 0.05). WS-CoQ10, cisplatin and the combination of WS-CoQ10
and cisplatin did not increase the total number of NPBs (Table 1).
The determination of the extent of DNA damage by WS-CoQ10,
cisplatin and their combination in the comet assay are shown in
Fig. 1 No evidence of a genotoxic effect was observed in the PC12
cells after exposure to WS-CoQ10 (0.1, 0.5 and 1.0 mg mL1), and
the % DNA in the tail after treatment with WS-CoQ10 did not differ
statistically from the negative control.
Exposure to cisplatin (0.1 mg mL1) did not increase the % DNA
in the tail when compared with the negative control. Similarly, the
combination of WS-CoQ10 and cisplatin did not differ from the
cisplatin group with respect to the % DNA in tail (Fig. 1). The comet
assay included a positive control group (doxorubicin at a
concentration of 10.0 mg mL1), which differed signiﬁcantly for
all treatments (p < 0.05).
3.2. mRNA expression levels of Tp53 were not regulated by WS-CoQ10
Fig. 2 shows the mRNA expression levels of Tp53 after 48 h of
treatment with WS-CoQ10 and cisplatin alone or in combination.
The mRNA expression levels of Tp53 did not change when the PC12
cells were exposed to 1.0 mg mL1 WS-CoQ10.
When the PC12 cells were exposed to cisplatin (0.1 mg mL1),
the mRNA expression levels of Tp53 signiﬁcantly increasedFig. 1. Percentage of DNA (% DNA) in the tail of PC12 cells treated for 3 h with water-so
assay. The data represent three independent experiments and are displayed as the mean
*Signiﬁcantly different from the negative control (p < 0.05). #Signiﬁcantly different from t(p < 0.05) when compared with the negative control (Fig. 2).
WS-CoQ10 in combination with cisplatin did not change the mRNA
expression levels of Tp53 when compared with the cisplatin group.
3.3. Neuroprotective effects of WS-CoQ10
The neurite outgrowth assay evaluated the neuroprotective
effect of WS-CoQ10 on cisplatin-treated cells. Fig. 3 shows the
results of the stimulation or inhibition of neurite outgrowth in the
NGF-dPC12 cells treated with WS-CoQ10, cisplatin or WS-CoQ10 in
combination with cisplatin. WS-CoQ10 (0.1 and 1.0 mg mL1)
showed a similar mean % of neurites compared with the negative
control, indicating that WS-CoQ10 was not neurotoxic to the NGF-
dPC12 cells. Cisplatin (10.0 mg mL1) signiﬁcantly inhibited the
neurite outgrowth, indicating high levels of neurite toxicity. WS-
CoQ10 at concentration of 0.1 mg mL1 signiﬁcantly stimulated the
cisplatin inhibition of neurite outgrowth when compared with the
cisplatin group (p < 0.05).
3.4. Changes in the total intracellular GSH
PC12 cells exposed to cisplatin (0.1 mg mL1) exhibited a
signiﬁcant reduction (p < 0.05) in the amount of GSH + 2GSSG
(Fig. 4). These results indicated that PC12 cells did not undergo a
process of resistance to cisplatin once cisplatin treatment depleted
the GSH system, compared to untreated cells.
The level of GSH + 2GSSG in the PC12 cells treated with WS-
CoQ10 (0.1, 0.5 and 1.0 mg mL1) alone or in combination withluble coenzyme Q10 (WS-CoQ10) and cisplatin alone or in combination in a comet
  SD (standard deviation). Doxorubicin (10.0 mg mL1) was used as a positive control.
he cisplatin treatment (p < 0.05).
Fig. 2. Relative expression levels of Tp53 mRNA in PC12 cells after treatment with
WS-CoQ10 and cisplatin alone or in combination. Housekeeping gene b-actin was
analysed for normalisation of the RT-qPCR reaction. The data represent the
mean  SD (standard deviation) of three independent experiments. *Signiﬁcantly
different from the negative control (p < 0.05).
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GSH + 2GSSG in the negative control.
4. Discussion
The neuroprotective effect of WS-CoQ10 against cisplatin-
induced neurotoxicity was evaluated in PC12 cells to determine if
WS-CoQ10 is able to protect a neuronal cell model from the
neurotoxic effects of cisplatin. Our results showed that WS-CoQ10
reduced cisplatin-induced DNA damage and stimulated cisplatin-
inhibited neurite outgrowth.
The DNA damage was evaluated using a CBMN Cyt assay and a
comet assay. Using these assays, we found that WS-CoQ10 did not
increase the frequency of DNA damage biomarkers MNi, NBUDs
and NPBs and maintained a similar level of % DNA in the tail
compared with a negative control, suggesting that WS-CoQ10
produced no genotoxic effects in PC12 cells. Although previous
research demonstrated that CoQ10 did not increase the frequency
of MNi in the bone marrow of mice and rats (Fu et al., 2009) or in
human lymphocytes (Migliore et al., 2004), genotoxicity studies ofFig. 3. Neurite outgrowth in NGF-differentiated PC12 cells in response to treatment wit
mean  SD (standard deviation) of three independent experiments. *Signiﬁcantly different fr
(p < 0.05).WS-CoQ10 using the CBMN Cyt assay have not been reported in the
literature. A previous comet assay also conﬁrmed that treatment
with WS-CoQ10 did not induce DNA damage in differentiated
human neuroblastoma (SHSY) cells (McCarthy et al., 2004).
Analysis of DNA damage biomarkers indicated that cisplatin
(0.1 mg mL1) increased the frequency of MNi and NBUDs in PC12
cells. Similar results were previously described using the
micronucleus test (Dos Santos et al., 2012; Mendonca et al.,
2009), indicating an increase in the frequency of MNi in PC12 cells
after treatment with cisplatin. Using the CBMN Cyt assay, it was
possible to show that treatment with cisplatin increased the
frequency of NBUDs and did not induce the formation of NPBs in
PC12 cells. The nuclear budding process is a measure of ampliﬁed
DNA and has been associated with extrusions resulting in MNi
(Fenech, 2007; Fenech et al., 2011). In the comet assay, the % DNA
in the tail after treatment with cisplatin was similar to that of the
negative control. This result was due the capacity of cisplatin to
form DNA–DNA or DNA–protein crosslinks with DNA (Pfuhler and
Wolf, 1996), which reduces the migration of DNA on agarose gels
(Tice et al., 2000). Cisplatin–DNA adducts interfere with DNA
transcription and are a major mechanism of cytotoxicity in
cancerous cells (Basu and Krishnamurthy, 2010).
In the CBMN Cyt assay, the combination of WS-CoQ10 and
cisplatin reduced the frequency of MNi and NBUDs, exhibiting
protective activity in PC12 cells. Because DNA damage-induced
neurotoxicity is related to diseases of the nervous system (Hetman
et al., 2010), this results suggests that WS-CoQ10 has the potential
to act as a protective agent for neuronal cells. In the comet assay,
WS-CoQ10 applied simultaneously with cisplatin did not change
the % DNA in the tail compared to cisplatin alone, suggesting that
WS-CoQ10 may not act by altering the binding of cisplatin to DNA,
which is one of the principal mechanisms of cisplatin cytotoxicity.
Previous studies showed that CoQ10 reduced cisplatin-induced
nephrotoxicity (Fouad et al., 2010) and decreased the cardiotoxi-
city of the chemotherapeutical agent doxorubicin without
interfering with its anticancer activity (Greenlee et al., 2012).
Several studies correlate cisplatin and DNA damage with p53
activity because the mechanism of action of cisplatin is related
DNA damage, and the p53 protein is involved in DNA damage
signalling (Basu and Krishnamurthy, 2010). Cisplatin induces
apoptosis by binding to DNA in Dorsal Root Ganglion Neurons,
resulting in DNA damage and subsequent p53 activation (Park
et al., 2000; Podratz et al., 2011). Furthermore, the p53 protein hash WS-CoQ10 and cisplatin alone or in combination for 72 h. The data represent the
om the negative control (p < 0.05). #Signiﬁcantly different from the cisplatin treatment
Fig. 4. The amount of GSH + 2 GSSG in PC12 cells exposed to WS-CoQ10 and cisplatin alone or in combination. The data represent the mean  SD (standard deviation) of three
independent experiments. *Signiﬁcantly different from the negative control (p < 0.05).
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Krishnamurthy, 2010).
The TP53 gene product is activated in response to various types
of DNA damage and regulates cellular processes such as cell cycle
arrest, apoptosis and DNA repair (Ford, 2005). In the absence of
DNA damage, the p53 protein is maintained at low concentrations
within cells, implying that there is a mechanism for the constant
degradation of this molecule (Appella and Anderson, 2001). Our
results demonstrated that WS-CoQ10 does not regulate the
expression levels of Tp53 mRNA in PC12 cells. A recent study
showed that the Mediterranean diet supplemented with CoQ10
self-regulated Tp53 expression and decreased concentrations of
p53 in the cytoplasm (Gutierrez-Mariscal et al., 2012).
Studies have demonstrated that elevated levels of p53 protein
in response to treatment with DNA-damaging agents could be used
as an indicator of damage induced by genotoxic agents (Salazar
et al., 2009; Yang and Duerksen-Hughes, 1998). In this study, the
increased expression levels of Tp53 mRNA after cisplatin treatment
was also related to an increase in DNA damage (as shown by the
increase in the MNi and NBUDs frequencies). Our results suggest
there is a relationship between cisplatin-induced DNA damage and
the levels of Tp53 mRNA in PC12 cells.
In addition to causing DNA damage and increasing expression
levels of Tp53 mRNA, cisplatin also acts directly on sensory
nerves and causes neurotoxicity and mitochondrial dysfunction
(Mendonca et al., 2013; Podratz et al., 2011). In our study, cisplatin
(10.0 mg mL1) induced a high degree of neurite toxicity in NGF-
differentiated PC12 cells, which is most likely due to an increase in
ROS generation, cisplatin binding to DNA and DNA damage.
Administered alone, WS-CoQ10 was not neurotoxic to NGF-
differentiated PC12 cells by a neurite outgrowth assay, and when
administered with cisplatin, WS-CoQ10 (0.1 mg mL1) stimulated
cisplatin-inhibited neurite outgrowth. How WS-CoQ10 speciﬁcally
stimulates cisplatin-inhibited neurite outgrowth is as yet un-
known, however, it may be related to the free radical scavenging
and antioxidant activity of WS-CoQ10.
In experimental models, WS-CoQ10 showed neuroprotective
effects related to its antioxidant activity (Somayajulu-Nitu et al.,
2009; Somayajulu et al., 2005). In addition to WS-CoQ10, other
agents, such as amifostine and phenoxodiol, have also demon-
strated neuroprotective activity in NGF-differentiated PC12 cells
and have reduced cisplatin-induced neurotoxicity (Klein et al.,
2007; Verstappen et al., 2004). However, these agents wereineffective with regards to treatment with high concentrations of
cisplatin (10.0 mg mL1) for 24 h, which differs from the neuro-
protective effect of WS-CoQ10 demonstrated in this study.
An increase in the intracellular concentration of GSH is a
common mechanism of resistance to anticancer drugs (Zhang et al.,
1998). This process is one of the known mechanisms of cisplatin
resistance in cell cultures, in which GSH is conjugated with
cisplatin to form a complex that reduces the biological potential of
anticancer agent (Chen and Kuo, 2010; Godwin et al., 1992). In this
study, the results of the GSH system evaluation showed that PC12
cells were not resistant to cisplatin because the treatment with
cisplatin depleted intracellular levels of GSH and GSSG compared
to untreated cells.
The combination of WS-CoQ10 and cisplatin restored the GSH
system to close to the levels of the negative control. This effect
likely occurred not through a cisplatin resistance mechanism but
because of the antioxidant activity of WS-CoQ10, a process that has
been demonstrated in other studies with CoQ10 (Somayajulu-Nitu
et al., 2009; Somayajulu et al., 2005; Yang et al., 2009).
5. Conclusion
In conclusion, it was demonstrated that WS-CoQ10 exhibits
neuroprotective activity in PC12 cells, reducing DNA damage and
cisplatin-induced neuritic toxicity. The neuroprotective effect of
WS-CoQ10 found in our study, in addition to its widely described
biological activities, suggests a potential application in chemo-
therapeutic protocols.
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